Breaking News Instant updates and real-time market news.

DOVA

Dova Pharmaceuticals

$20.14

-0.05 (-0.25%)

, BBBY

Bed Bath & Beyond

$9.89

0.09 (0.92%)

09:10
09/30/19
09/30
09:10
09/30/19
09:10

Fly Intel: Pre-market Movers

HIGHER: Dova Pharmaceuticals (DOVA), up 39% after entering into an agreement and plan of merger with Swedish Orphan Biovitrum, or Sobi. Under the terms of the agreement, an indirect subsidiary of Sobi will commence a tender offer for all outstanding shares of Dova, whereby Dova stockholders will be offered an upfront payment for $27.50 per share in cash, along with one non-tradeable contingent value right that entitles them to an additional $1.50 per share in cash upon regulatory approval of DOPTELET... Bed Bath & Beyond (BBBY), up 7% after Wedbush analyst Seth Basham upgraded the stock to Outperform from Neutral and raised his price target for the shares to $16 from $14. Bed Bath & Beyond has a "good chance of stabilization" in earnings over the next two years as its changes take hold, Basham tells investors... Calithera Biosciences (CALA), up 9% after presenting new data from the investigational oral arginase inhibitor INCB001158 as a monotherapy and in combination with the checkpoint inhibitor pembrolizumab in microsatellite stable colorectal carcinoma patients... Mallinckrodt (MNK), up 5% after executing a definitive settlement agreement and release with Cuyahoga and Summit Counties in Ohio in connection with lawsuits pending in multidistrict opioid litigation in the U.S. District Court for the Northern District of Ohio... Colony Capital (CLNY), up 3% after entering into definitive agreements for Blackstone Real Estate Partners IX to acquire Colony Industrial, the industrial real estate assets and affiliated industrial operating platform of Colony Capital, for an aggregate purchase price of $5.9B. LOWER: Immunomedics (IMMU), down 7.5% after presenting interim data from the 100-patient cohort of cisplatin-eligible patients of the company's TROPHY-U-01 open-label Phase 2 study. In this interim report, sacituzumab govitecan produced an overall response rate of 29% in 35 patients with metastatic urothelial cancer who have relapsed or are refractory to immune checkpoint inhibitors and platinum-based chemotherapy... Teekay LNG (TGP) and Teekay Corp. (TK), down 7% and 5%, respectively, after postponing their group investor day.

DOVA

Dova Pharmaceuticals

$20.14

-0.05 (-0.25%)

BBBY

Bed Bath & Beyond

$9.89

0.09 (0.92%)

CALA

Calithera Biosciences

$3.27

-0.01 (-0.30%)

MNK

Mallinckrodt

$2.26

-0.02 (-0.88%)

CLNY

Colony Capital

$5.90

0.15 (2.61%)

IMMU

Immunomedics

$14.33

-0.02 (-0.14%)

TGP

Teekay LNG

$15.12

-0.34 (-2.20%)

TK

Teekay Corp.

$4.23

-0.24 (-5.37%)

  • 30

    Sep

  • 30

    Sep

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

DOVA Dova Pharmaceuticals
$20.14

-0.05 (-0.25%)

08/29/19
08/29/19
INITIATION
Target $30

Outperform
Oppenheimer bullish on Dova Pharmaceuticals, initiates with an Outperform
As previously reported, Oppenheimer analyst Justin Kim started coverage of Dova Pharmaceuticals with an Outperform rating and $30 price target. In the midst of a commercial expansion into chronic immune thrombocytopenia, the analyst views the company's Doptelet - a thrombopoietin receptor agonist, treating plateletrelated deficiencies - as a best-in-breed therapy for an already defined commercial market. In the $1B U.S. ITP market alone, Kim believes strong commercial execution could re-rate the shares.
08/29/19
08/29/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NXP Semiconductors (NXPI) initiated with a Buy at Loop Capital. 2. Exponent (EXPO) initiated with a Neutral at DA Davidson. 3. Dova Pharmaceuticals (DOVA) initiated with an Outperform at Oppenheimer. 4. Cree (CREE) initiated with an Underperform at Exane BNP Paribas. 5. MarketAxess (MKTX) initiated with a Hold at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/19/19
HCWC
09/19/19
NO CHANGE
Target $45
HCWC
Buy
Dova Pharmaceuticals price target raised to $45 from $39 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Dova Pharmaceuticals to $45 from $39 saying the top-line data readout of the Phase 3 Doptelet trial in chemotherapy-induced thrombocytopenia is approaching shortly, expected in the first half of 2020. The analyst sees see upside potential for Dova in chemotherapy-induced thrombocytopenia as there are no approved therapies for it. He keeps a Buy rating on Dova Pharmaceuticals.
08/28/19
OPCO
08/28/19
INITIATION
Target $30
OPCO
Outperform
Dova Pharmaceuticals initiated with an Outperform at Oppenheimer
Oppenheimer started Dova Pharmaceuticals with an Outperform rating and $30 price target.
BBBY Bed Bath & Beyond
$9.89

0.09 (0.92%)

08/20/19
BOFA
08/20/19
NO CHANGE
Target $20
BOFA
Buy
Bed Bath & Beyond price target lowered to $20 from $21 at BofA/Merrill
BofA/Merrill analyst Curtis Nagle told investors in a research note that he is cautious on near-term trends for Bed Bath & Beyond, as it is operating without a permanent CEO and has yet to take any major steps to stage a turnaround after years of underperformance under the old executive team. The analyst, who lowered his FY19-FY21 EPS estimates to $1.89/$2.28/$2.87 from $1.96/$2.49/$3.09, lowered his price target to $20 from $21, and says he continues to see the fall as a reasonable timeframe for a new CEO announcement and decisions about selling non-core assets and 4.6 million square feet of owned real estate. Nagel reiterates a Buy rating, as he continues to see many avenues for earnings upside.
08/09/19
EVER
08/09/19
UPGRADE
EVER
In Line
Bed Bath & Beyond upgraded to In Line from Underperform at Evercore ISI
09/30/19
WEDB
09/30/19
UPGRADE
WEDB
Outperform
Bed Bath & Beyond upgraded to Outperform from Neutral at Wedbush
09/30/19
WEDB
09/30/19
UPGRADE
Target $16
WEDB
Outperform
Wedbush upgrades Bed Bath & Beyond to Outperform, sees 62% upside potential
Wedbush analyst Seth Basham upgraded Bed Bath & Beyond to Outperform from Neutral and raised his price target for the shares to $16 from $14, which represents 62% upside potential. The retailer closed Friday up 9c to $9.89. Turning around declining retailers is a very difficult task, particularly amidst unfavorable secular trends and soft industry sales growth, but Bed Bath & Beyond has a "good chance of stabilization" in earnings over the next two years as its changes take hold, Basham tells investors in a research note. The company has a reconstituted board with "much-improved" governance, is resetting its cost structure, has a plan to reduce inventory by 35%, is rapidly refreshing stores to improve the shopping experience, has launched two private label brands, and is evaluating opportunities to leverage its store lease expiration cadence and sell noncore assets, explains the analyst. Further, Basham believes buy-side expectations are "very low."
CALA Calithera Biosciences
$3.27

-0.01 (-0.30%)

05/30/19
SBSH
05/30/19
INITIATION
Target $10
SBSH
Buy
Calithera Biosciences assumed with a Buy at Citi
Citi analyst Mohit Bansal assumed coverage Calithera Biosciences with a Buy rating and $10 price target. Under a prior analyst, Citi had a Buy rating on the shares with a $7 price target. Positive data mid-year from the small metastatic renal cell carcinoma trial could have read-through to the Cabo trial, Bansal tells investors in a research note.
MNK Mallinckrodt
$2.26

-0.02 (-0.88%)

09/09/19
STFL
09/09/19
NO CHANGE
Target $8
STFL
Hold
Mallinckrodt price target lowered to $8 from $20 at Stifel
Stifel analyst Annabel Samimy lowered her price target for Mallinckrodt shares to $8 from $20 after she reduced her expected growth of Acthar for 2019 and beyond and factored in more concrete potential litigation cash-calls. She models a $300M potential settlement with CMS related to the Acthar AMP-pricing reversion and has included a $900M potential liability for opioid-litigation payments, calling those her "best, reasonable estimates at this point" but acknowledging there still remains considerable uncertainty around both issues. Mallinckrodt's settlement of Track 1 of the Ohio multi-district litigations is "only a small step in the sprawling opioid litigation," but the settlement buys the company much-needed time to address New York state litigation or a global settlement, said Samimy, who keeps a Hold rating on Mallinckrodt shares.
09/05/19
09/05/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. BHP Group (BHP) downgraded to Underperform from Neutral at Exane BNP Paribas. 2. Mallinckrodt (MNK) downgraded to Market Perform from Outperform at BMO Capital analyst Gary Nachman citing yesterday's Bloomberg reports that the company hired restructuring firms to help manage through its opioid litigation. 3. Yirendai (YRD) downgraded to Underperform from Neutral at Macquarie with analyst Dexter Hsu saying the company not only reported "disappointing" Q2 results, but also closed the merger with CreditEase on unfavorable terms. 4. Green Dot (GDOT) downgraded to Hold from Buy at Jefferies with analyst John Hecht saying the company's organic revenue growth has been slowing and it is trying to establish share in a new customer target market with well-resourced competitors. 5. Royal Dutch Shell (RDS.A, RDS.B) downgraded to Market Perform from Outperform at Cowen with analyst Jason Gabelman saying the downgrade reflects its peer leading exposure to international gas prices which are forecasted lower through 2020 and as a result could limit its free cash flow growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/05/19
09/05/19
DOWNGRADE
Target $3

Market Perform
Mallinckrodt cut to Market Perform at BMO Capital on opioid restructuring report
As previously reported, BMO Capital analyst Gary Nachman downgraded Mallinckrodt to Market Perform and slashed his price target to $3 from $19 after yesterday's Bloomberg reports that the company hired restructuring firms to help manage through its opioid litigation. The analyst contends that an already challenging situation has "taken a turn for the worse", stating that he previously believed that the company would be able to navigate through these issues. Nachman adds that with the mounting pressures related to the litigation, the possibility of bankruptcy for Mallinckrodt can no longer be ruled out.
09/10/19
STFL
09/10/19
NO CHANGE
STFL
Mallinckrodt's sale of BioVectra helps alleviate cash pressure, says Stifel
Stifel analyst Annabel Samimy maintained a Hold rating and $8 price target on Mallinckrodt, but noted that Mallinckrodt announced the sale of its CDMO organization, BioVectra, to HIG Capital for a potential $250M, which the analyst believes is "a positive step to manage and bolster cash and maintain capital allocation priorities." Samimy added that, with the departure of Specialty Generics President Matthew Harbaugh, the company's suspension of the spin-off appears indefinite.
CLNY Colony Capital
$5.90

0.15 (2.61%)

10/05/18
10/05/18
NO CHANGE

Colony Industrial acquires nine industrial properties in Atlanta
Colony Industrial announced it has acquired the Atlanta NE/I-85 Industrial Portfolio consisting of nine Class A warehouse properties in Atlanta, Georgia, in a transaction that closed on September 26, 2018. Colony Industrial is the light industrial platform of Colony Capital. The properties are located in Atlanta's prime Northeast industrial submarket, totaling 890,920 square feet in six buildings at 2150 Boggs Road Northwest in Duluth, GA; one building at 1645 Satellite Boulevard in Duluth, GA; and two buildings at 2925 and 3255 Shawnee Industrial Way in Suwanee, GA. Their location offers immediate access to Interstate 85, a major north-south corridor connecting Atlanta to Charlotte and the Mid-Atlantic. The buildings are 96% leased to 23 high-quality tenants.
07/05/19
RILY
07/05/19
NO CHANGE
Target $8
RILY
Buy
Northstar Realty Europe sale positive for Colony Capital, says B. Riley FBR
B. Riley FBR analyst Randy Binner views the sale of Northstar Realty Europe (NRE) as a positive for Colony Capital (CLNY). The analyst reiterates a Buy rating on Colony with an $8 price target.
IMMU Immunomedics
$14.33

-0.02 (-0.14%)

09/10/19
JEFF
09/10/19
NO CHANGE
JEFF
Buy
Immunomedics competitor shows 'impressive' efficacy, AEs cause concern, says Jefferies
Jefferies analyst Chris Howerton says that Immunomedics competitor DS-1062 showed "impressive" efficacy of 70%-plus cORR at RP2D, but he notes that n=7 is "quite small," and baseline characteristics could be different. Importantly, the analyst points out that one patient died of respiratory failure, and four reported potential ILD since data cutoff, including one death. Overall, he does not view DS-1062 as near-term comparable to IMMU-132's current pipeline. Howerton reiterates a Buy rating and $22 price target on Immunomedics' shares.
08/20/19
08/20/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Immunomedics (IMMU) initiated with an Overweight at Cantor Fitzgerald. 2. PayPal (PYPL) initiated with a Buy at Rosenblatt while Square (SQ) was initiated with a Neutral. 3. Sunrun (RUN), Vivint Solar (VSLR), and Sunnova Energy (NOVA) initiated with an Overweight at KeyBanc. 4. Spotify (SPOT) initiated with an Equal Weight at Consumer Edge. 5. Silk Road Medical (SILK) initiated with a Buy at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/10/19
PIPR
09/10/19
NO CHANGE
PIPR
Overweight
Safety signals arise for potential Immunomedics competitor, says Piper Jaffray
Daiichi today reported updated Phase I data for its TROP2 antibody drug conjugate DS-1062 in non-small cell lung cancer, and while the drug's efficacy continues to impress, there do appear to be some safety signals popping up, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. Specifically, dose-limiting toxicities associated with skin rash/stomatitis were reported, which is notable as development of Pfizer's (PFE) TROP2 antibody drug conjugate was discontinued for excess skin rash and mucosa toxicity, adds the analyst. These data may or may not dampen concerns around DS-1062 being a competitive threat to Immunomedics' sacituzumab, says Catanzaro. However, he continues to believe Immunomedics is "very well-positioned" within triple-negative breast cancer and urothelial bladder cancer. The analyst reiterates an Overweight rating on the shares with a $20 price target. Following Daiichi's data, shares of Immunomedics are up 8% to $14.30.
09/29/19
PIPR
09/29/19
NO CHANGE
Target $20
PIPR
Overweight
Piper Jaffray says some may be disappointed by Immunomedics TROPHY response rate
Piper Jaffray analyst Joseph Catanzaro notes that Immunomedics (IMMU) presented interim data from the Phase II TROPHY study of sacituzumab govitecan in postchemo/CPI urothelial bladder cancer at ESMO. Overall, the response rate of 29% is consistent with prior Phase I data, but he does believe some could be disappointed by this number as it relates to Seattle Genetics' (SGEN) 44% ORR for EV. Catanzaro would await more mature data before drawing any definitive conclusions on the competitive positioning of sacituzumab and EV in post-chemo/IO UBC, but ultimately believes the SC ORR in a larger cohort is approvable and that both drugs will play important roles in this landscape. He reirerates an Overweight rating and $20 price target on Immunomedics's shares.
TGP Teekay LNG
$15.12

-0.34 (-2.20%)

11/21/18
WELS
11/21/18
NO CHANGE
Target $15
WELS
Outperform
Teekay LNG price target lowered to $15 from $22 at Wells Fargo
Wells Fargo analyst Michael Webber lowered his price target for Teekay LNG to $15 from $22 following quarterly results. The analyst reiterates an Outperform rating on the shares.
11/28/18
STFL
11/28/18
UPGRADE
Target $20
STFL
Buy
Teekay LNG upgraded to Buy from Hold at Stifel
Stifel analyst Benjamin Nolan upgraded Teekay LNG Partners to Buy with a $20 price target. While the recent distribution increase is not as large as some would have hoped, it enables the partnership to "aggressively attack debt and eventually grow organically," Nolan tells investors in a research note. Further, Teekay announced that a plan to amend its tax structure in order to remove the K-1 filing burden on the units, which opens the door to a broader base of investors as a 1099 filer, says the analyst. He sees "no further overhangs to valuation improvement" and believes Teekay LNG units are "simply too cheap to ignore."
01/22/19
MSCO
01/22/19
UPGRADE
MSCO
Overweight
Teekay LNG upgraded to Overweight from Equal Weight at Morgan Stanley
01/22/19
01/22/19
UPGRADE
Target $16

Overweight
Teekay LNG upgraded to Overweight following 45% pullback at Morgan Stanley
As previously reported, Morgan Stanley analyst Fotis Giannakoulis upgraded Teekay LNG to Overweight from Equal Weight following the recent selloff, stating that he believes prior consensus distribution expectations were "too lofty," but he now believes consensus estimates are on the low side following revisions lower. After the stock lost 45% of its value in 2018, the risks are now are skewed to the upside, contends Giannakoulis, who lowered his price target on Teekay LNG shares to $16 from $17.50.
TK Teekay Corp.
$4.23

-0.24 (-5.37%)

10/22/18
BOFA
10/22/18
INITIATION
Target $8
BOFA
Buy
Teekay Corp. initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Melvin Shieh initiated Teekay Corp with a Buy and $8 price target. Shieh is bullish on Teekay's outlook saying he expects potential upside from secular growth of liquefied natural gas and petroleum gas, a recovery in product and crude tanker markets, and demand for energy commodities.
01/22/19
01/22/19
DOWNGRADE
Target $1

Underweight
Teekay Offshore Partners downgraded to Underweight at Morgan Stanley
As previously reported, Morgan Stanley analyst Fotis Giannakoulis downgraded Teekay Offshore Partners (TOO) to Underweight from Equal Weight, citing his lower oil price forecast and its impact on the Floating Production Storage and Offloading business. He sees lower oil prices putting pressure on its oil linked FPSO contracts and making redeployment of its assets more difficult, Giannakoulis tells investors. He cut his price target on Teekay Offshore Partners shares to $1 from $2.75 and also lowered his price target on Teekay Corporation (TK) to $3 from $6.50.

TODAY'S FREE FLY STORIES

ETNB

89bio

$26.03

3.03 (13.17%)

, YAYO

YayYo

$3.65

-0.29 (-7.36%)

11:09
11/17/19
11/17
11:09
11/17/19
11:09
On The Fly
Opening Day: 89bio has strong opening week »

89bio (ETNB) finished its…

ETNB

89bio

$26.03

3.03 (13.17%)

YAYO

YayYo

$3.65

-0.29 (-7.36%)

CAN

Canaan

$0.00

(0.00%)

SITM

SiTime

$0.00

(0.00%)

BABA

Alibaba

$185.44

2.75 (1.51%)

YXR

YX Asset Recovery

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

WFC

Wells Fargo

$53.80

0.3 (0.56%)

, AAPL

Apple

$265.73

3.07 (1.17%)

10:01
11/16/19
11/16
10:01
11/16/19
10:01
Periodicals
Berkshire Hathaway inactive with record cash hoard, Barron's says »

Berkshire Hathaway…

WFC

Wells Fargo

$53.80

0.3 (0.56%)

AAPL

Apple

$265.73

3.07 (1.17%)

OXY

Occidental Petroleum

$38.94

1.18 (3.13%)

BRK.B

Berkshire Hathaway

$219.74

0.38 (0.17%)

BRK.A

Berkshire Hathaway

$329,361.11

266.11 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

DIS

Disney

$144.63

-2.56 (-1.74%)

09:43
11/16/19
11/16
09:43
11/16/19
09:43
Periodicals
Disney+ may not be able to hold onto huge number of subs, Barron's says »

While Disney's (DIS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$112.11

2.9 (2.66%)

09:27
11/16/19
11/16
09:27
11/16/19
09:27
Periodicals
Medtronic shares 'could rise even more,' Barron's says »

Barron's recommended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BR

Broadridge

$119.80

0.485 (0.41%)

09:18
11/16/19
11/16
09:18
11/16/19
09:18
Periodicals
Broadridge a defensive name that can withstand slowdown, Barron's says »

Broadridge Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$193.95

-0.02 (-0.01%)

, MDT

Medtronic

$112.11

2.9 (2.66%)

09:07
11/16/19
11/16
09:07
11/16/19
09:07
Periodicals
Barron's suggests dividend stocks for retirement savers »

In this week's…

MCD

McDonald's

$193.95

-0.02 (-0.01%)

MDT

Medtronic

$112.11

2.9 (2.66%)

KO

Coca-Cola

$52.67

0.03 (0.06%)

PRU

Prudential

$93.61

0.82 (0.88%)

SYF

Synchrony

$37.05

0.34 (0.93%)

KEY

KeyCorp

$18.96

0.1 (0.53%)

T

AT&T

$39.49

0.53 (1.36%)

AMGN

Amgen

$220.84

2.29 (1.05%)

CSCO

Cisco

$45.10

0.18 (0.40%)

RCL

Royal Caribbean

$117.91

2.69 (2.33%)

MRK

Merck

$84.89

0.33 (0.39%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

JPM

JPMorgan

$129.51

0.83 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 02

    Dec

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 14

    Jan

  • 21

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 14

    Mar

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

, MSFT

Microsoft

$149.95

1.89 (1.28%)

08:54
11/16/19
11/16
08:54
11/16/19
08:54
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

AAPL

Apple

$265.73

3.07 (1.17%)

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

THC

Tenet

$30.55

1.08 (3.66%)

GM

General Motors

$36.87

0.07 (0.19%)

FCAU

Fiat Chrysler

$16.02

0.04 (0.25%)

TM

Toyota

$144.29

1.16 (0.81%)

F

Ford

$8.96

0.16 (1.82%)

HMC

Honda

$28.99

0.155 (0.54%)

VWAGY

Volkswagen

$0.00

(0.00%)

BMWYY

BMW

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 04

    Feb

  • 06

    Feb

MDCO

The Medicines Co.

$51.92

1.03 (2.02%)

04:55
11/16/19
11/16
04:55
11/16/19
04:55
Conference/Events
Roth Capital pharmaceuticals analysts to hold a luncheon »

Analysts host Dr. John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

CVET

Covetrus

$14.93

1.44 (10.67%)

18:41
11/15/19
11/15
18:41
11/15/19
18:41
Hot Stocks
Covetrus CEO: We're a leader in the humanization of pets »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSK

Comcast

$0.00

(0.00%)

, CMCSA

Comcast

$44.54

-0.93 (-2.05%)

18:02
11/15/19
11/15
18:02
11/15/19
18:02
Hot Stocks
Viacom extends cable deal for 'The Office' through 2025 »

Viacom (VIA) announced…

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

VIAB

Viacom

$23.07

0.59 (2.62%)

VIA

Viacom

$26.59

1.28 (5.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CWK

Cushman & Wakefield

$19.10

0.1 (0.53%)

17:48
11/15/19
11/15
17:48
11/15/19
17:48
Hot Stocks
Cushman & Wakefield CEO sells 84.6K share of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

LMT

Lockheed Martin

$393.52

3.305 (0.85%)

17:39
11/15/19
11/15
17:39
11/15/19
17:39
Hot Stocks
Lockheed Martin awarded maximum $3.33B Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESCA

Escalade

$10.90

-0.09 (-0.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Escalade CEO Fetherman to retire »

Escalade announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.96

0.1 (0.78%)

, ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Eldorado, Caesars stockholders approve Eldorado acquisition of Caesars »

Eldorado Resorts (ERI)…

CZR

Caesars

$12.96

0.1 (0.78%)

ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EGRX

Eagle Pharmaceuticals

$57.24

0.55 (0.97%)

17:15
11/15/19
11/15
17:15
11/15/19
17:15
Syndicate
Breaking Syndicate news story on Eagle Pharmaceuticals »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$60.82

0.84 (1.40%)

17:11
11/15/19
11/15
17:11
11/15/19
17:11
Hot Stocks
Fabrinet President Gill sells 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

TEUM

Pareteum

$0.38

-0.0209 (-5.21%)

17:05
11/15/19
11/15
17:05
11/15/19
17:05
Hot Stocks
Pareteum receives noncompliance notice from Nasdaq »

Pareteum announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEXO

Hexo

$1.78

-0.1 (-5.32%)

17:00
11/15/19
11/15
17:00
11/15/19
17:00
Hot Stocks
Hexo was cannabis was being grown in unlicensed space at Niagara site »

HEXO Corp provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$220.84

2.29 (1.05%)

, CELG

Celgene

$110.02

-0.01 (-0.01%)

16:57
11/15/19
11/15
16:57
11/15/19
16:57
Hot Stocks
Bristol-Myers gets FTC clearance for Celgene acquisition »

Bristol-Myers Squibb…

AMGN

Amgen

$220.84

2.29 (1.05%)

CELG

Celgene

$110.02

-0.01 (-0.01%)

BMY

Bristol-Myers

$58.61

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 04

    Dec

  • 07

    Dec

  • 25

    Mar

  • 04

    Apr

RAVE

Rave Restaurant

$1.44

-0.79 (-35.43%)

16:47
11/15/19
11/15
16:47
11/15/19
16:47
Hot Stocks
BBRC Asset Management reports 6.6% passive stake in Rave Restaurant »

BBRC Asset Management …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHAP

Chaparral Energy

$0.89

-0.0521 (-5.52%)

16:46
11/15/19
11/15
16:46
11/15/19
16:46
Hot Stocks
Chaparral Energy receives continued listing standard notice from NYSE »

Chaparral Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

CI

Cigna

$196.08

6.41 (3.38%)

, CNC

Centene

$57.57

2.91 (5.32%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks closed out the…

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

NVDA

Nvidia

$204.12

-5.76 (-2.74%)

AMZN

Amazon.com

$1,739.33

-15.38 (-0.88%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

UAA

Under Armour

$17.78

0.65 (3.79%)

UA

Under Armour

$15.97

0.41 (2.64%)

AMRN

Amarin

$23.99

2.5 (11.63%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

GOOG

Alphabet

$1,334.01

21.82 (1.66%)

GOOGL

Alphabet Class A

$1,333.33

23.54 (1.80%)

ORCL

Oracle

$56.43

0.33 (0.59%)

RH

RH

$188.73

13.535 (7.73%)

QGEN

Qiagen

$40.56

3.255 (8.73%)

FTCH

Farfetch

$9.66

2.17 (28.97%)

THC

Tenet

$30.55

1.08 (3.66%)

TORC

resTORbio

$1.10

-6.83 (-86.13%)

ACB

Aurora Cannabis

$2.72

-0.57 (-17.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 28

    Dec

  • 06

    Jan

  • 21

    Jan

  • 06

    Feb

NYT

New York Times

$31.60

0.44 (1.41%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
New York Times CEO sells 66,000 class A common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.